PCSK9 inhibitors. Recommendations for patient selection

被引：1
作者：
Laufs, U. [1 ]
Custodis, F. [1 ]
Werner, C. [1 ]
机构：
[1] Univ Klinikum Saarlandes, Klin Innere Med Kardiol Angiol & Internist Intens, IMED Geb 41-1, D-66421 Homburg, Germany
来源：
HERZ | 2016年 / 41卷 / 04期
关键词：
Proprotein convertase subtilisin-kexin type 9; Safety; Cholesterol; Risk; Review; CORONARY-HEART-DISEASE; SUBTILISIN/KEXIN TYPE 9; DENSITY-LIPOPROTEIN CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MONOCLONAL-ANTIBODY; STATIN THERAPY; CARDIOVASCULAR EVENTS; LDL-CHOLESTEROL; REDUCING LIPIDS; AMG; 145;
D O I：
10.1007/s00059-016-4429-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The 2 or 4aEuroweek subcutaneous therapy with the recently approved antibodies alirocumab and evolocumab for inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) reduces low-density lipoprotein cholesterol (LDL-C) in addition to statins and ezetimibe by 50-60 %. The therapy is well-tolerated. The safety profile in the published studies is comparable to placebo. Outcome data and information on long-term safety and the influence on cardiovascular events are not yet available but the results of several large trials are expected in 2016-2018. At present (spring 2016) PCSK9 inhibitors represent an option for selected patients with a high cardiovascular risk and high LDL-C despite treatment with the maximum tolerated oral lipid-lowering therapy. This group includes selected patients with familial hypercholesterolemia and high-risk individuals with statin-associated muscle symptoms (SAMS).
引用
收藏
页码：296 / 306
页数：11
相关论文
共 43 条
  • [21] Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
    Kuhnast, Susan
    van der Hoorn, Jose W. A.
    Pieterman, Elsbet J.
    van den Hoek, Anita M.
    Sasiela, William J.
    Gusarova, Viktoria
    Peyman, Anusch
    Schaefer, Hans-Ludwig
    Schwahn, Uwe
    Jukema, J. Wouter
    Princen, Hans M. G.
    [J]. JOURNAL OF LIPID RESEARCH, 2014, 55 (10) : 2103 - 2112
  • [22] Treatment Options for Statin-Associated Muscle Symptoms
    Laufs, Ulrich
    Scharnagl, Hubert
    Halle, Martin
    Windler, Eberhard
    Endres, Matthias
    Maerz, Winfried
    [J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2015, 112 (44): : 748 - U21
  • [23] Simplified algorithm to facilitate communication of familial hypercholesterolaemia
    Laufs, Ulrich
    Parhofer, Klaus G.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (43) : 3004 - 3006
  • [24] Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
    Le May, Cedric
    Kourimate, Sanae
    Langhi, Cedric
    Chetiveaux, Maud
    Jarry, Anne
    Comera, Christine
    Collet, Xavier
    Kuipers, Folkert
    Krempf, Michel
    Cariou, Bertrand
    Costet, Philippe
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (05) : 684 - U157
  • [25] PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
    Levy, Emile
    Ouadda, Ali Ben Djoudi
    Spahis, Schohraya
    Sane, Alain Theophile
    Garofalo, Carole
    Grenier, Emilie
    Emonnot, Lea
    Yara, Sabrina
    Couture, Patrick
    Beaulieu, Jean-Francois
    Menard, Daniel
    Seidah, Nabil G.
    Elchebly, Mounib
    [J]. ATHEROSCLEROSIS, 2013, 227 (02) : 297 - 306
  • [26] A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia
    Marks, D
    Thorogood, M
    Neil, HAW
    Humphries, SE
    [J]. ATHEROSCLEROSIS, 2003, 168 (01) : 1 - 14
  • [27] Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice
    Maxwell, KN
    Soccio, RE
    Duncan, EM
    Schayek, E
    Breslow, JL
    [J]. JOURNAL OF LIPID RESEARCH, 2003, 44 (11) : 2109 - 2119
  • [28] Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
    Moriarty, Patrick M.
    Jacobson, Terry A.
    Bruckert, Eric
    Thompson, Paul D.
    Guyton, John R.
    Baccara-Dinet, Marie T.
    Gipe, Daniel
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (06) : 554 - 561
  • [29] Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
    Nordestgaard, Borge G.
    Chapman, M. John
    Humphries, Steve E.
    Ginsberg, Henry N.
    Masana, Luis
    Descamps, Olivier S.
    Wiklund, Olov
    Hegele, Robert A.
    Raal, Frederick J.
    Defesche, Joep C.
    Wiegman, Albert
    Santos, Raul D.
    Watts, Gerald F.
    Parhofer, Klaus G.
    Hovingh, G. Kees
    Kovanen, Petri T.
    Boileau, Catherine
    Averna, Maurizio
    Boren, Jan
    Bruckert, Eric
    Catapano, Alberico L.
    Kuivenhoven, Jan Albert
    Pajukanta, Paeivi
    Ray, Kausik
    Stalenhoef, Anton F. H.
    Stroes, Erik
    Taskinen, Marja-Riitta
    Tybjaerg-Hansen, Anne
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 (45) : 3478 - +
  • [30] Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
    Park, SW
    Moon, YA
    Horton, JD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (48) : 50630 - 50638
12345